Strategy for Treating the Gastric Cancer: A Systematic Review and Meta-analysis

Document Type : Review Article

Authors

1 Department of Internal Medicine, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Cardiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

3 School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

4 Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran

Abstract

Background and aim: Contemporary approaches to treat the stage IV patients could be generally divided into five groups of the palliative gastrectomy, radiotherapy, Chemotherapy, bypass, and gastric stent. The present systematic review and meta-analysis evaluated the overall survival to treat stage IV gastric cancer (GC) based on distinct signs and prognosis.
Materials and methods: MEDLINE, PubMed, Cochrane Library, Embase, ISI, google scholar have been utilized as the electronic databases for searching systematic literature until 2019. Then, Endnote X9, which is one of the software programs in the market, has been applied to manage the titles electronically. Searches were performed with keywords, “Gastric cancer”, “cancer”,” Gastric”,” Stage IV”, “Radiotherapy” “Chemotherapy” , “Gastrectomy”, “treatment of gastric cancer”, “bypass”.
Results: A total of 150, 93, 21 studies respective abstracts and topics have been discovered in the course of manual and electronic searches in the internet. Finally, a total of 10 studies for Palliative gastrectomy, five studies for Chemotherapy, and three studies for Radiotherapy  required for this systematic review.
Conclusion: According to the meta-analysis, palliative gastrectomy exhibited a statistically significant survival advantage for the patients with the untreatable developed GC.

Keywords

Main Subjects


  1. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC. Chemotherapy for advanced gastric cancer. Cochrane Database of Syst Rev. 2017, Issue 8. Art. No.: CS004604.
  2. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. The Lancet. 2016;388(10060):2654-64.
  3. Ji L, Selleck MJ, Morgan JW, Xu J, Babcock BD, Shavlik D, Wall NR, Langridge WH, Lum SS, Garberoglio CA, Reeves ME. Gastric cancer peritoneal carcinomatosis risk score. Annals of surgical oncology. 2020 Jan 1;27(1):240-7.
  4. Izuishi K, Mori H. Recent strategies for treating stage IV gastric cancer: roles of palliative gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver Dis. 2016 Mar 1;25(1):87-94.
  5. Oliveros Wilches R, Facundo H, Bonilla González C, Sánchez Pedraza R. Case Report of Conversion Therapy in Stage IV Gastric Cancer. Colombian Journal of Gastroenterology. 2018 Mar; 33 (1): 61-7.
  6. Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016 Apr 1;19(2):329-38.
  7. Yang B, Wu G, Wang X, Zhang X. Discussion of modifying stage IV gastric cancer based on Borrmann classification. Tumor Biology. 2013;34(3):1485-91.
  8. Jin H, Zhang G, Liu X, Liu X, Chen C, Yu H, Huang X, Zhang Q, Yu J. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy. World journal of surgical oncology. 2013 Dec 1;11(1):112.
  9. Gong W, Yang S, Yang X, Guo F. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. Clinics. 2016 Jun;71(6):311-4.
  10. Asakura H, Hashimoto T, Harada H, Mizumoto M, Furutani K, Hasuike N, Matsuoka M, Ono H, Boku N, Nishimura T. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate?. Journal of cancer research and clinical oncology. 2011 Jan 1;137(1):125-30.
  11. Kawabata R, Kameda C, Takata A, Yasuyama A, Matsumura T, Koga C, Murakami M, Hirota M, Noura S, Shimizu J, Chatani M. A Case of Unresectable Advanced Gastric Cancer Treated with Palliative Radiation Therapy for Massive Bleeding. Gan to kagaku ryoho. Cancer & chemotherapy. 2017 Nov;44(12):1653-5.
  12. Lee YH, Lee JW, Jang HS. Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer. BMC cancer. 2017 Dec 1;17(1):541.
  13. Lupascu C, Andronic D, Ursulescu C, Vasiluta C, Raileanu G, Georgescu S, Niculescu D, Crumpei F, Tarcoveanu E. Palliative gastrectomy in patients with stage IV gastric cancer–our recent experience. Chirurgia (Bucur). 2010 Jul 1;105(4):473-6.
  14. Zhang JZ, Lu HS, Huang CM, Wu XY, Wang C, Guan GX, Zhen JW, Huang HG, Zhang XF. Outcome of palliative total gastrectomy for stage IV proximal gastric cancer. The American journal of surgery. 2011 Jul 1;202(1):91-6.
  15. Sougioultzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J, Dokou A, Tzivras D, Zografos G, Felekouras E, Papalambros E. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. European Journal of Surgical Oncology (EJSO). 2011 Apr 1;37(4):312-8.
  16. Kim KH, Lee KW, Baek SK, Chang HJ, Kim YJ, Park DJ, Kim JH, Kim HH, Lee JS. Survival benefit of gastrectomy±metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer. 2011 Jun 1;14(2):130-8.
  17. Chang YR, Han DS, Kong SH, Lee HJ, Kim SH, Kim WH, Yang HK. The value of palliative gastrectomy in gastric cancer with distant metastasis. Annals of surgical oncology. 2012 Apr 1;19(4):1231-9.
  18. Kokkola A, Louhimo J, Puolakkainen P. Does non‐curative gastrectomy improve survival in patients with metastatic gastric cancer?. Journal of surgical oncology. 2012 Aug 1;106(2):193-6.
  19. Chen S, Li YF, Feng XY, Zhou ZW, Yuan XH, Chen YB. Significance of palliative gastrectomy for late‐stage gastric cancer patients. Journal of surgical oncology. 2012 Dec 1;106(7):862-71.
  20. Tokunaga M, Terashima M, Tanizawa Y, Bando E, Kawamura T, Yasui H, Boku N. Survival benefit of palliative gastrectomy in gastric cancer patients with peritoneal metastasis. World journal of surgery. 2012 Nov 1;36(11):2637-43.
  21. Miki Y, Fujitani K, Hirao M, Kurokawa Y, Mano M, Tsujie M, Miyamoto A, Nakamori S, Tsujinaka T. Significance of surgical treatment of liver metastases from gastric cancer. Anticancer research. 2012 Feb 1;32(2):665-70.
  22. Dittmar Y, Rauchfuss F, Goetz M, Jandt K, Scheuerlein H, Heise M, Settmacher U. Non-curative gastric resection for patients with stage 4 gastric cancer—a single center experience and current review of literature. Langenbeck's archives of surgery. 2012 Jun 1;397(5):745-53.
  23. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010 Aug 28;376(9742):687-97.
  24. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. Journal of Clinical Oncology. 2012 Aug 1;30(22):2718-24.
  25. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2014 Jan 4;383(9911):31-9.
  26. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The lancet oncology. 2014 Jan 1;15(1):78-86.
  27. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The lancet oncology. 2014 Oct 1;15(11):1224-35.
  28. Kotan C, Sumer A, Baser M, Kızıltan R, Carparlar MA. An analysis of 13 patients with perforated gastric carcinoma: A surgeon's nightmare?. World Journal of Emergency Surgery. 2008 Dec 1;3(1):17.
  29. Vasas P, Wiggins T, Chaudry A, Bryant C, Hughes FS. Emergency presentation of the gastric cancer; prognosis and implications for service planning. World Journal of Emergency Surgery. 2012 Dec 1;7(1):31.
  30. Melloni M, Bernardi D, Asti E, Bonavina L. Perforated Gastric Cancer: A Systematic Review. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2019 Sep 23.
  31. Nishitani M, Yoshida N, Tsuji S, Masunaga T, Hirai H, Miyajima S, Dejima A, Nakashima T, Wakita S, Takemura K, Minato H. Optimal number of endoscopic biopsies for diagnosis of early gastric cancer. Endoscopy International Open. 2019 Dec;7(12):E1683-90.
  32. Ajani JA, Bentrem DJ, Besh S, D’Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA. Gastric cancer, version 2.2013. Journal of the national comprehensive cancer network. 2013 May 1;11(5):531-46.
  33. Hallissey MT, Allum WH, Fielding JW, Roginski C. Palliative surgery for gastric cancer. Cancer. 1988 Jul 15;62(2):440-4.
  34. Sun J, Chen X, Gao P, Song Y, Huang X, Yang Y, Zhao J, Ma B, Gao X, Wang Z. Can the neutrophil to lymphocyte ratio be used to determine gastric cancer treatment outcomes? A systematic review and meta-analysis. Disease markers. 2016;2016.
  35. Kim DY, Joo JK, Park YK, Ryu SY, Kim YJ, Kim SK, Lee JH. Is palliative resection necessary for gastric carcinoma patients?. Langenbeck's archives of surgery. 2008 Jan 1;393(1):31-5.
  36. Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer research. 2014 May 1;34(5):2079-85.
  37. Ito S, Oki E, Nakashima Y, Ando K, Hiyoshi Y, Ohgaki K, Saeki H, Morita M, Sakaguchi Y, Maehara Y. Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. Anticancer research. 2015 Jan 1;35(1):401-6.
  38. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Annals of oncology. 2009 Sep 1;20(9):1529-34.

 

Volume 2, Issue 1
March 2020
Pages 6-11
  • Receive Date: 15 January 2020
  • Revise Date: 29 February 2020
  • Accept Date: 10 March 2020
  • First Publish Date: 10 March 2020